Seer Return on Investment 2020-2022 | SEER
Current and historical return on investment (ROI) values for Seer (SEER) over the last 10 years.
| Seer ROI - Return on Investment Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | LT Investments & Debt | Return on Investment |
| 2022-03-31 | $-0.08B | inf% | |
| 2021-12-31 | $-0.07B | inf% | |
| 2021-09-30 | $-0.06B | inf% | |
| 2021-06-30 | $-0.05B | inf% | |
| 2021-03-31 | $-0.04B | inf% | |
| 2020-12-31 | $-0.03B | inf% | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Biomedical and Genetics | $0.559B | $0.007B |
| Seer Inc. is a life sciences company. It engages in developing Proteograph(TM), which is an integrated solution consisting of consumables, automation instrumentation and proprietary software. Seer Inc. is based in REDWOOD CITY, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bristol Myers Squibb (BMY) | United States | $163.938B | 9.97 |
| Bio-Rad Laboratories (BIO.B) | United States | $14.121B | 30.63 |
| QIAGEN (QGEN) | Netherlands | $10.718B | 16.92 |
| Biohaven Pharmaceutical Holding (BHVN) | United States | $10.276B | 0.00 |
| Ginkgo Bioworks Holdings (DNA) | United States | $4.228B | 0.00 |
| Arcus Biosciences (RCUS) | United States | $1.817B | 46.07 |
| Emergent Biosolutions (EBS) | United States | $1.560B | 6.68 |
| Myovant Sciences (MYOV) | United Kingdom | $1.185B | 0.00 |
| Zymeworks (ZYME) | Canada | $0.306B | 0.00 |
| Gelesis Holdings (GLS) | United States | $0.112B | 0.00 |
| Ambrx Biopharma (AMAM) | United States | $0.102B | 0.00 |
| Enzo Biochem (ENZ) | United States | $0.101B | 0.00 |
| SQZ Biotechnologies (SQZ) | United States | $0.090B | 0.00 |
| ADC Therapeutics SA (ADCT) | Switzerland | $0.000B | 0.00 |
